| Literature DB >> 36013007 |
Bright Benfor1, Julia Högl1, Ryan Gouveia E Melo1, Jan Stana1, Carlota Fernandez Prendes1, Maximilian Pichlmaier2, Barbara Rantner1, Nikolaos Tsilimparis1.
Abstract
BACKGROUND: The outcome of FBEVAR in post-dissection thoracoabdominal aortic aneurysms has not been well established in the literature. The aim of this study was to compare midterm outcomes following FBEVAR in post-dissection aneurysms to degenerative aneurysms. (2)Entities:
Keywords: BEVAR; FEVAR; branched endovascular aortic repair; complex aortic aneurysms; fenestrated endovascular aortic repair; thoracoabdominal aortic aneurysms
Year: 2022 PMID: 36013007 PMCID: PMC9409799 DOI: 10.3390/jcm11164768
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Demographics and baseline characteristics of patients undergoing fenestrated and branched endovascular repair for thoraco-abdominal and abdominal aneurysms.
| Variable * | All Patients | Degenerative | Post-Dissection | |
|---|---|---|---|---|
|
|
|
|
|
|
| Gender, Female | 31(22.6) | 21 (19.6) | 10 (33.3) | 0.113 |
| BMI, kg/m2 | 26.8 ± 4.9 | 26.6 ± 4.9 | 27.4 ± 4.9 | 0.416 |
| ASA score | 0.443 | |||
| 2 | 3 (2.2) | 3 (2.8) | 0 (0.0) | |
| 3 | 101 (73.7) | 80 (74.7) | 21 (70.0) | |
| 4 | 32 (23.4) | 23 (21.5) | 9 (30.0) | |
| Ejection fraction, % | 62.7 ± 11.7 | 61.4 ± 12.6 | 66.9 ± 6.3 | 0.099 |
| Cardiovascular Comorbidities | ||||
|
|
|
|
|
|
| MI | 9 (6.6) | 8 (7.5) | 1(3.3) | 0.683 |
| Arrhythmia | 35 (25.5) | 29 (27.1) | 6 (20.0) | 0.416 |
| CHF | 17 (12.4) | 16 (15.0) | 1 (3.3) | 0.086 |
| Hypertension | 112 (81.7) | 85 (79.4) | 27 (90.0) | 0.213 |
| Ischemic stroke or TIA | 17 (12.4) | 16 (15.0) | 1 (3.3) | 0.119 |
| PAD | 17 (12.4) | 14 (13.1) | 3 (10.0) | 0.764 |
| Diabetes mellitus | 18 (13.1) | 17 (15.9) | 1(3.3) | 0.122 |
|
|
|
|
|
|
| COPD | 24 (17.5) | 21 (19.6) | 3 (10.0) | 0.283 |
| GFR, ml/min | 67.9 ± 23.0 | 67.0 ± 21.2 | 71.1 ± 28.3 | 0.381 |
| Connective tissue disorder | 2(1.5) | 1 (0.9) | 1 (3.3) | 0.394 |
| Antiplatelet therapy | 120 (87.6) | 94 (87.9) | 26 (86.7) | 0.999 |
| Statin use | 92 (67.2) | 75 (70.1) | 17 (56.7) | 0.145 |
| ACE inhibitors | 95 (69.3) | 74 (69.2) | 21 (70.0) | 0.984 |
| Betablockers | 92 (67.2) | 68 (63.6) | 24 (80.0) | 0.101 |
| Hostile abdomen | 18 (13.2) | 16 (15.0) | 2 (6.7) | 0.299 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endovascular | 28 (20.4) | 18 (16.8) | 10 (33.3) | |
| Open | 10 (7.3) | 4 (3.8) | 6 (20.0) | |
| Both | 11 (8.0) | 2 (1.9) | 9 (30.0) | |
| Aneurysm size | 61.9± 15.4 | 63.2± 16.1 | 57.4± 11.9 | 0.067 |
| Status of aneurysm | 0.133 | |||
| Asymptomatic | 117 (85.4) | 89 (83.2) | 29(96.7) | |
| Symptomatic non-ruptured | 14(10.2) | 13(12.1) | 1(3.3) | |
| Ruptured | 6(4.4) | 6(5.6) | 0(0) | |
|
|
| |||
| Extensive TAAA (I-III) | 42 (30.7) | 21 (19.6) | 21 (70.0) | |
| AAA/Crawford IV | 95 (69.3) | 86 (80.4) | 9 (30.0) | |
|
|
|
|
|
|
| Iliac tortuosity index ( | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.1 | 0.098 |
AAA: abdominal aortic aneurysm; ACE: angiotensin-converting enzyme; CAD: coronary heart disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; MISACE: minimally-invasive segmental artery coil embolization; PAD: peripheral heart disease; TAAA: thoracoabdominal aortic aneurysm. * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).
Figure 1Bar graph of type of target vessel incorporation in fenestrated/branched endovascular aortic repair; CT: coeliac trunk; SMA: superior mesenteric artery; RRA: right renal artery; LRA: left renal artery; ARA: accessory renal artery.
Figure 2Bridging stents used to incorporate the reno-mesenteric arteries in fenestrated and branched endovascular repair of the aorta; CT: coeliac trunk; SMA: superior mesenteric artery; RRA: right renal artery; LRA: left renal artery.
Intraoperative details of patients undergoing fenestrated and branched endovascular thoraco-abdominal and abdominal aortic repair.
| Variable * | All Patients | Degenerative | Post-Dissection | |
|---|---|---|---|---|
| ( | ( | ( | ||
| Surgical setting | 0.048 | |||
| Elective | 117 (85.4) | 88 (82.2) | 29 (96.7) | |
| Urgent/Emergency | 20 (14.6) | 19 (17.8) | 1 (3.3) | |
| Type of endograft | 0.052 | |||
| Custom-made | 111 (81.0) | 83 (77.6) | 28(93.3) | |
| Off-the-shelf | 16 (11.7) | 14 (13.1) | 2 (6.7) | |
| Surgeon-modified | 10 (7.3) | 10 (9.3) | 0(0.0) | |
| Inverted limb | 17 (12.41) | 16 (15.0) | 1 (3.3) | 0.088 |
| Preloaded catheter | 13 (9.5) | 11 (10.3) | 2 (6.7) | 0.55 |
| Percutaneous femoral access | 123 (89.8) | 96 (89.7) | 27 (90.0) | 0.99 |
| N° of Target vessels | 3.6 ± 0.8 | 3.6 ± 0.8 | 3.9 ± 0.3 | 0.095 |
| CT | 106 (77) | 77 (72) | 29(96.7) | 0.004 |
| SMA | 125 (91) | 95 (88.8) | 30 (100) | 0.068 |
| RRA | 130 (94.9) | 103 (96) | 27 (90) | 0.177 |
| LRA | 134 (97.8) | 107 (100) | 30 (100) | 0.999 |
| ARA | 7 (5) | 7 (6) | 0 (0) | 0.347 |
| N° of Target vessels ≥4 | 100 (73.0) | 74 (69.0) | 26 (86.7) | 0.056 |
| Type of incorporation | ||||
| n | 505 | 388 | 117 | |
| Scallop | 22(4.4) | 22(5.7) | 0(0) | 0.008 |
| Fenestrations | 333 (65.9) | 241 (62) | 92 (78.6) | 0.001 |
| Branches | 150 (29.7) | 125 (32) | 25 (21.4) | 0.024 |
| Bridging stent diameter, mm | ||||
| CT | 8 ± 2 | 8 ± 2 | 9 ± 1 | 0.008 |
| SMA | 8 ± 1 | 8 ± 1 | 8 ± 1 | 0.17 |
| RRA | 6 ± 1 | 6 ± 1 | 7 ± 1 | 0.040 |
| LRA | 7 ± 1 | 6 ± 1 | 7 ± 1 | 0.011 |
| Bridging stent sealing length, mm ± SD | ||||
| CT | 43 ± 26 | 45 ± 28 | 38 ± 18 | 0.26 |
| SMA | 46 ± 24 | 47 ± 23 | 45 ± 26 | 0.74 |
| RRA | 40 ± 24 | 40 ± 25 | 40 ± 23 | 0.97 |
| LRA | 40 ± 23 | 39 ± 23 | 42 ± 24 | 0.54 |
| Adjunctive procedures | 41 (29.9) | 24 (22.4) | 17 (56.7) | <0.001 |
| Bifurcation relining | 14 (10.2) | 7 (6.5) | 7 (23.3) | 0.014 |
| Iliac side branch | 31 (22.6) | 18 (16.8) | 13(43.3) | 0.002 |
| Fusion | 51 (37.3) | 41 (38.3) | 10 (33.3) | 0.62 |
| CSF drainage | 69 (50.4) | 45 (42.1) | 24 (80.0) | <0.001 |
| Contrast volume, mL | 300 (200–400) | 300 (200–400) | 400 (300–500) | 0.009 |
| Fluoroscopy time, min | 83 (61–115) | 81 (60–116) | 89 (71–115) | 0.74 |
| Radiation dose, mGy | 3255 (2035–5889) | 3134 (2035–5909) | 4624 (1849–5736) | 0.75 |
| Total procedural time, min | 261 (203–333) | 255 (196–334) | 272 (232–315) | 0.73 |
| Technical success | 133 (97.1) | 105 (98.1) | 28 (97.1) | 0.21 |
| Endoleak at final angio | 22 (16.0) | 17 (15.9) | 5 (16.7) | 0.99 |
| Type I | 4 (2.9) | 1 (0.9) | 3 (10.0) | 0.033 |
| Type II | 16 (11.7) | 14 (13.1) | 2 (6.7) | 0.52 |
| Type IIIc | 2 (1.5) | 2 (1.9) | 0 (0.0) | 0.45 |
CT: celiac trunk; LRA: left renal artery; RRA: right renal artery; SMA: superior mesenteric artery. * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).
Comparative analysis of 30-day outcomes of FBEVAR in post-dissection and degenerative aneurysms.
| Outcome * | All | Degenerative | Post-Dissection | ||||
|---|---|---|---|---|---|---|---|
| MACE | 16 | (11.8) | 15 | (14) | 1 | (3.5) | 0.19 |
| Myocardial infarction | 8 | (5.8) | 8 | (7.5) | 0 | (0.0) | 0.20 |
| Acute heart failure | 11 | (8.0) | 10 | (9.9) | 1 | (3.3) | 0.46 |
| Ischemic stroke | 4 | (2.9) | 4 | (3.7) | 0 | (0.0) | 0.57 |
| Respiratory complications | 10 | (7.3) | 9 | (8.4) | 1 | (3.3) | 0.69 |
| Acute kidney injury | 16 | (11.7) | 12 | (11.2) | 4 | (13.0) | 0.75 |
| No dialysis | 12 | (8.8) | 10 | (9.4) | 2 | (6.7) | - |
| Temporary dialysis | 3 | (2.2) | 1 | (0.9) | 2 | (6.7) | - |
| Permanent dialysis | 1 | (0.7) | 1 | (0.9) | 0 | (0.0) | - |
| Spinal cord injury | 10 | (7.5) | 9 | (8.7) | 1 | (3.3) | 0.45 |
| Paraplegia | 5 | (3.8) | 5 | (4.9) | 0 | (0.0) | - |
| Paresis | 5 | (3.8) | 4 | (3.8) | 1 | (3.3) | - |
| Ischemic colitis | 2 | (1.5) | 2 | (1.9) | 0 | (0.0) | 0.99 |
| Access vessel complication | |||||||
| Femoral access | 10 | (7.3) | 8 | (7.5) | 2 | (6.7) | 0.999 |
| Upper access | 2 | (1.5) | 2 | (1.90 | 0 | (0.0) | 0.999 |
| Surgical wound complication | 4 | (2.9) | 4 | (3.7) | 0 | (0.0) | 0.576 |
| Endoleak | |||||||
| Type I & III | 21 | (15.3) | 11 | (10.3) | 10 | (33.0) | 0.004 |
| Ia | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - |
| Ib | 7 | (4.7) | 1 | (0.9) | 6 | (20.0) | <0.001 |
| Ic | 1 | (0.7) | 0 | (0.0) | 1 | (0.8) | - |
| IIIa | 6 | (4.4) | 6 | (5.6) | 0 | (0.0) | 0.33 |
| IIIc | 7 | (5.1) | 4 | (3.7) | 3 | (10.0) | 0.18 |
| Type II | 10 | (7.3) | 8 | (7.5) | 2 | (6.7) | 0.99 |
| Postoperative LOS, days | 9 | (7–16) | 9 | (7–20) | 8.5 | (7–11) | 0.50 |
| ICU length of stay, days | 2 | (1–4) | 2 | (1–4) | 3 | (2–4) | 0.89 |
| Reintervention | 8 | (5.9) | 7 | (6.5) | 1 | (3.5) | 0.99 |
| Mortality | 4 | (2.9) | 4 | (3.7) | 0 | (0.0) | 0.58 |
ICU: Intensive care unit; LOS: length of stay; MACE: major adverse cardiovascular event. * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).
Short-term outcomes.
| Outcome * | All | Degenerative | Post-Dissection | ||||
|---|---|---|---|---|---|---|---|
| Follow-up, months, m (sd) | 15.2 | (13.1) | 15.2 | (13.3) | 15.3 | (12.5) | 0.82 |
| Late Endoleak, | 37 | (27.8) | 23 | (22.3) | 14 | (46.7) | 0.009 |
| Type I | 11 | (8.8) | 3 | (2.8) | 8 | (30.0) | <0.001 |
| Ia | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - |
| Ib | 8 | (6.0) | 3 | (2.9) | 5 | (16.7) | 0.015 |
| Ic | 3 | (2.3) | 0 | (0.0) | 3 | (10.0) | 0.011 |
| Type II | 11 | (8.3) | 8 | (7.8) | 3 | (10.0) | 0.71 |
| Type III | 15 | (11.0) | 12 | (11.2) | 3 | (10.0) | 0.85 |
| IIIa | 13 | (9.5) | 10 | (9.4) | 3 | (10.0) | 0.7 |
| IIIb | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - |
| IIIc | 2 | (1.5) | 2 | (1.9) | 0 | (0.0) | 0.99 |
| Graft limb occlusion | 7 | (5.3) | 4 | (3.9) | 3 | (10.0) | 0.19 |
| Aneurysm rupture | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Aneurysm sac change, mm/year | −0.1 | (−7.0; 3.0) | −0.95 | (−7.0; 2.2) | 1.6 | (−2.8; 7.3) | 0.40 |
| Sac shrinkage | 28 | (26.2) | 22 | (26.8) | 6 | (26.2) | 0.78 |
| Sac progression | 22 | (20.6) | 13 | (15.9) | 9 | (36.0) | 0.029 |
| Unchanged diameter | 57 | (53.3) | 47 | (57.3) | 10 | (40.0) | 0.13 |
| Late reintervention | 27 | (20.3) | 18 | (17.5) | 9 | (20.3) | 0.13 |
| Target vessel relining/recanalization | 11 | (8.3) | 5 | (4.9) | 6 | (20.0) | 0.016 |
| CT | 2 | (1.5) | 1 | (1.0) | 1 | (3.3) | 0.40 |
| SMA | 3 | (2.3) | 1 | (1.0) | 2 | (6.7) | 0.13 |
| RRA | 4 | (3.0) | 2 | (1.9) | 2 | (6.7) | 0.21 |
| LRA | 6 | (4.5) | 2 | (1.9) | 4 | (13.3) | 0.023 |
| Death | 9 | (6.8) | 9 | (8.7) | 0 | 0 | 0.094 |
CT: celiac trunk; LRA: left renal artery; RRA: right renal artery; SMA: superior mesenteric artery; * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range). † Four deaths occurred at 30 days and are excluded from analysis.
Figure 3Kaplan–Meier failure plot of occurrence of type I and III endoleaks after fenestrated/branched endovascular aortic repair.
Figure 4Kaplan–Meier failure plot of occurrence of type I and III endoleaks after fenestrated/branched endovascular aortic repair.
Univariate analysis of factors associated with graft-related reintervention in 137 patients undergoing fenestrated/branched aortic repair.
| Variable | OR | CI95 | |
|---|---|---|---|
| Total procedure time > 240 min | 5.3 | (1.7–16.2) | 0.002 |
| Adjunctive procedures | 3.0 | (1.3–7.1) | 0.009 |
| Age < 60 years | 4.7 | (1.7–13.0) | 0.002 |
| Female gender | 1.9 | (0.8–4.8) | 0.177 |
| Extensive TAAA | 2.0 | (0.5–4.5) | 0.116 |
| Post-dissection aneurysm | 3.1 | (1.2–7.6) | 0.013 |
OR: odds-ratio; CI: confidence interval.
Figure 5Kaplan–Meier survival estimates of freedom from all-cause mortality in patients undergoing fenestrated/branched endovascular aortic repair.